回盛生物
(300871)
| 流通市值：17.19亿 | | | 总市值：17.19亿 |
| 流通股本：1.66亿 | | | 总股本：1.66亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 792,553,431.27 | 436,303,723.6 | 206,809,092.09 | 1,019,758,798.36 |
| 营业收入 | 792,553,431.27 | 436,303,723.6 | 206,809,092.09 | 1,019,758,798.36 |
| 二、营业总成本 | 838,141,263.93 | 468,045,931.31 | 219,314,493.26 | 1,016,321,252.34 |
| 营业成本 | 662,167,979.36 | 353,277,702.42 | 159,934,252.24 | 806,465,634.79 |
| 税金及附加 | 7,340,513.41 | 4,641,663.07 | 2,307,708.03 | 9,529,403.11 |
| 销售费用 | 44,509,417.85 | 29,001,399.62 | 14,341,963.29 | 55,628,365.22 |
| 管理费用 | 52,357,035.94 | 34,982,278.61 | 18,413,255.46 | 75,680,149.1 |
| 研发费用 | 38,952,745.03 | 26,461,413.27 | 14,535,112.78 | 44,597,573.76 |
| 财务费用 | 32,813,572.34 | 19,681,474.32 | 9,782,201.46 | 24,420,126.36 |
| 其中:利息费用 | 34,195,217.14 | 21,516,123.43 | 10,410,980.81 | 28,215,682.33 |
| 其中:利息收入 | 1,458,036.27 | 1,121,276.81 | 777,622.73 | 4,349,899.17 |
| 加:公允价值变动收益 | -37,453,462.24 | -49,002,063.88 | -18,092,751.86 | 12,252,419.77 |
| 加:投资收益 | 7,430,344.39 | 5,747,399.98 | 3,345,414.97 | 13,122,321.17 |
| 资产减值损失(新) | -1,582,610.81 | -3,096,367.8 | -2,036,523.66 | -2,643,840.37 |
| 信用减值损失(新) | 3,939,216.38 | 5,963,681.72 | 4,174,706.75 | -25,161,815.83 |
| 其他收益 | 12,119,476.6 | 7,495,427.4 | 3,627,361.16 | 14,076,355.18 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -61,134,868.34 | -64,634,130.29 | -21,487,193.81 | 15,082,985.94 |
| 加:营业外收入 | 77,279.57 | 59,723.92 | 43,056.73 | 208,713.44 |
| 减:营业外支出 | 146,031.82 | 111,694.82 | 101,862.98 | 2,850,153.76 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -61,203,620.59 | -64,686,101.19 | -21,546,000.06 | 12,441,545.62 |
| 减:所得税费用 | -13,587,630.42 | -12,807,044 | -5,140,383.26 | -4,339,273.15 |
| 六、净利润 | -47,615,990.17 | -51,879,057.19 | -16,405,616.8 | 16,780,818.77 |
| 持续经营净利润 | -47,615,990.17 | -51,879,057.19 | -16,405,616.8 | 16,780,818.77 |
| 归属于母公司股东的净利润 | -47,658,306.03 | -51,878,681.23 | -16,405,616.8 | 16,780,818.77 |
| 少数股东损益 | 42,315.86 | -375.96 | - | - |
| (一)基本每股收益 | -0.29 | -0.31 | -0.1 | 0.1 |
| (二)稀释每股收益 | -0.29 | -0.31 | -0.1 | 0.1 |
| 八、其他综合收益 | -767,307.88 | -1,587,603.84 | - | - |
| 归属于母公司股东的其他综合收益 | -767,307.88 | -1,587,603.84 | - | - |
| 九、综合收益总额 | -48,383,298.05 | -53,466,661.03 | -16,405,616.8 | 16,780,818.77 |
| 归属于母公司股东的综合收益总额 | -48,425,613.91 | -53,466,285.07 | -16,405,616.8 | 16,780,818.77 |
| 归属于少数股东的综合收益总额 | 42,315.86 | -375.96 | - | - |
| 公告日期 | 2024-10-30 | 2024-08-28 | 2024-04-25 | 2024-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |